← Leaderboards
John James Vrbanac
Tarn Biosciences, Inc.
$889,203
Attributed
$889,203
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $298.8K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$889,203 · 2
By mechanism
R41$889,203 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Inhibitor”
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Michael George Natchus · Emory University$10,548,554
- John Alam · Eip Pharma, Inc.$10,411,018
- Kenneth Schultz · Trethera Corporation$8,384,949
Research focus
InhibitorLicensingDrug Resistance In TuberculosisGranulomatousIn VitroLegal PatentChemistryDrug ResistanceFormulationGlobal HealthAnalogAqueousBacteriaIn VivoAmericanBiological AvailabilityBiological SciencesDisease TransmissionChronicEfficacy StudyCellsChronic InfectionCessation Of LifeLung
Grant awards (3)
Development of nitroreductase-activated inhibitors to treat mycobacterial infections$298,829
R41 · FY2025 · AI · contact PI
Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis$293,238
R41 · FY2024 · AI · contact PI
Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis$297,136
R41 · FY2023 · AI · contact PI